UNBRANDED NATIVE CTV CAMPAIGN GENERATES AVERAGE 88% LIFT IN ATTENTION FOR PHARMACEUTICAL BRAND
As one of the world's leading pharmaceutical corporations, this client leads the way when it comes to investing into researching and raising awareness of diseases that millions of us suffer from.
To amplify awareness of diabetic retinopathy as an urgent health condition, elevate understanding for the disease and increase visits to retina specialists to learn more about diabetic retinopathy.
Fusing dynamic native content animation with proprietary ad serving technology, Slingshot stitches and serves highly engaging 15s native content directly adjacent to regular ad creatives, inside commercial breaks on Connected TV.
FOR THIS ADVERTISER
Origin's team of writers and designers created a unique series of unbranded native ctv assets which would run directly adjacent to their scheduled ad creative.
It's primary goal was to draw eyeballs back to the screen ahead of the ad and create a sense of 'relevance' with the viewer.
The client's Native CTV campaign was distributed nationally using Origin's curated portfolio of premium media partners, each of whom we work with on an exclusively direct basis.
In addition to more general data segments, the client's Native CTV campaign was targeted towards households with a 'likely diagnosis of diabetic retinopathy'.
TOTAL IMPRESSIONS SERVED
TOTAL UNIQUE REACH
FREQUENCY PER HOUSEHOLD
THE OUTCOME WAS SIGNIFICANT
OVERALL LIFT IN ATTENTION
The client saw an average 88% increase in the physical attention viewers paid to their ad when it was amplified by Slingshot vs when it ran on its own.
Origin is a creative technology company whose pioneering Native CTV advertising solutions are reshaping the way brands engage and activate consumers on the largest screen in the home.
Fusing dynamic content animation with proprietary ad serving technology, Origin's proprietary Native CTV ad formats elevate attention, recall, consideration and outcomes for brands who want to amplify their presence on Connected TV.